# Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

> **NCT06334432** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nuvation Bio Inc.** · enrollment: 466 (estimated)

## Conditions studied

- Advanced Solid Tumor
- HER2-negative Breast Cancer
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Pancreatic Cancer
- Platinum-resistant Ovarian Cancer (PROC)

## Interventions

- **DRUG:** NUV-1511

## Key facts

- **NCT ID:** NCT06334432
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-14
- **Primary completion:** 2027-03
- **Final completion:** 2027-10
- **Target enrollment:** 466 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06334432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06334432, "Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06334432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*